Literature DB >> 4276573

Proceedings: CB 154 (2-bromo-alpha-ergokryptine, bromocriptin), a potential anti-Parkinson agent.

A M Johnson, J M Vigouret, D M Loew.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4276573

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  5 in total

1.  Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.

Authors:  A M Johnson; D M Loew; J M Vigouret
Journal:  Br J Pharmacol       Date:  1976-01       Impact factor: 8.739

2.  The influence of bromocriptine on serotonin neurons.

Authors:  J Maj; L Gancarczyk; A Rawlów
Journal:  J Neural Transm       Date:  1977       Impact factor: 3.575

3.  Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism.

Authors:  P Price; A Debono; J D Parkes; C D Marsden; J Rosenthaler
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

4.  The role of dopaminergic receptors in the behavioral effects induced by lisuride in male rats.

Authors:  G Baggio; F Ferrari
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

5.  Subchronic Oral Bromocriptine Methanesulfonate Enhances Open Field Novelty-Induced Behavior and Spatial Memory in Male Swiss Albino Mice.

Authors:  Olakunle James Onaolapo; Adejoke Yetunde Onaolapo
Journal:  Neurosci J       Date:  2012-12-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.